The Humanized Monoclonal anti-IL-6R (Tocilizumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect IL-6R (Tocilizumab Biosimilar) in samples from Human.
Catalog No. ABIN7795095
Quick Overview for Recombinant IL-6R (Tocilizumab Biosimilar) antibody (ABIN7795095)
Target
IL-6R (Tocilizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Conjugate
This IL-6R (Tocilizumab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Grade
Research Grade
Expression System
Mammalian cells
Purpose
Tocilizumab Biosimilar, Human IL-6R Monoclonal Antibody
Characteristics
What is tocilizumab biosimilar research grade? Tocilizumab biosimilar uses the same protein sequences as the therapeutic antibody tocilizumab. Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, fibroblasts. IL-6 rapidly induces C-reactive protein, serum amyloid A, fibrinogen, haptoglobin, and α-1-antichymotrypsin while inhibiting production of fibronectin, albumin, and transferrin. IL-6 also induces antibody production, induces cytotoxic T-cell differentiation, and inhibits regulatory T-cell differentiation. Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation.